How can constipation associated with buspirone (Buspar) be managed?

Management of Buspirone-Associated Constipation

Initiate polyethylene glycol (PEG) 17 grams once daily as first-line treatment for buspirone-induced constipation, combined with increased fluid intake and regular physical activity. 1, 2

Understanding Buspirone's Constipation Risk

Buspirone causes constipation as a documented adverse effect, with meta-analysis showing a significantly higher rate compared to placebo (OR = 4.11,95% CI: 1.34-12.55). 3 This represents a 4-fold increased risk that warrants proactive management. The FDA label does not specifically list constipation as a common adverse effect, though gastrointestinal distress is noted. 4

First-Line Treatment Algorithm

Start with PEG 17 grams (one heaping tablespoon) mixed in 8 ounces of water once daily. 1, 2 This recommendation comes from the American Gastroenterological Association's 2023 guidelines as the strongest evidence-based first-line agent for chronic constipation. 1

• Goal: Achieve one non-forced bowel movement every 1-2 days, not necessarily daily. 5, 2
• Increase fluid intake significantly, particularly if baseline consumption is low (aim for at least 2 liters daily). 1, 2
• Encourage regular physical activity to utilize the gastrocolic reflex. 2, 6

Alternative First-Line Options

If PEG is not tolerated or unavailable:

• Stimulant laxatives: Bisacodyl 5-10 mg once daily or senna 2-3 times daily 5, 2
• Milk of magnesia: 1 oz twice daily (cost-effective alternative) 2

Second-Line Treatment (If No Response After 4 Weeks)

Add a stimulant laxative to PEG rather than switching agents. 2, 6 The combination approach is more effective than monotherapy escalation.

Options to add:

• Bisacodyl 10-15 mg once daily 5, 2
• Senna 2-3 times daily 5, 2
• Alternative osmotic agents: Lactulose, magnesium hydroxide, or magnesium citrate (avoid magnesium salts in renal impairment) 1, 2

Third-Line Treatment for Refractory Cases

If constipation persists despite combination therapy:

• Consider prokinetic agents: Metoclopramide 10-20 mg 2-3 times daily, particularly if gastroparesis symptoms are present 2
• Newer secretagogues (refer to gastroenterology):
  • Linaclotide (guanylate cyclase-C agonist) - most efficacious for constipation but causes diarrhea 1, 2
  • Lubiprostone (chloride channel activator) - less likely to cause diarrhea than linaclotide 1, 2
  • Plecanatide (guanylate cyclase-C agonist) 1, 2

Critical Pitfalls to Avoid

• Never use stool softeners (docusate) alone - they lack efficacy as monotherapy and provide no additional benefit when combined with stimulant laxatives. 5, 2
• Do not add fiber supplements without ensuring adequate hydration (at least 2 liters daily) - this can worsen constipation in medication-induced cases. 5, 2
• Avoid fiber supplements entirely for medication-induced constipation - they are ineffective and may worsen symptoms. 5, 2
• Do not limit PEG to 7 days - it can be used safely long-term for chronic constipation. 6

Assessment Before Treatment

Perform digital rectal examination to rule out fecal impaction before initiating therapy. 2 If impaction is present:

• Glycerin suppository for mild impaction 5, 2
• Bisacodyl suppository 10 mg rectally for moderate impaction 5, 6
• Manual disimpaction may be necessary in severe cases 5, 6

Review medications to identify and discontinue other constipating agents when feasible (antacids, anticholinergics, antiemetics). 2

Rule out metabolic causes if constipation is severe or refractory: hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus. 2, 6

When to Reassess or Refer

• If constipation persists despite standard therapy, obtain abdominal imaging to exclude mechanical obstruction or severe fecal loading. 6
• Refer to gastroenterology if standard laxatives fail after 8-12 weeks for consideration of prescription secretagogues. 2, 6
• Immediately evaluate for bowel obstruction if patient develops severe abdominal pain, distension with absent bowel sounds, or worsening symptoms despite treatment. 5, 2

Buspirone Continuation Considerations

The FDA label does not require discontinuation of buspirone for constipation. 4 However, if constipation becomes severe or refractory to multiple interventions, discuss with the prescribing psychiatrist whether alternative anxiolytic therapy is appropriate, as buspirone's constipation risk is significantly higher than placebo. 3